Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous FMT in AML Patients (ODYSSEE)
NCT02928523Phase 2Completed
- Sponsor
- MaaT Pharma
- Start
- Jun 2016
- Primary completion
- Aug 2017
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MaaT011 in dysbiosis, sponsored by MaaT Pharma. Primary endpoints: Microbiota diversity (Simpson/Shannon index) at 40 days and Multidrug-resistant bacteria eradication at 40 days. Started Jun 2016; status: completed.
02
Drugs
MaaT011
03
Conditions
dysbiosis
Beyond the preview
Go deeper on NCT02928523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928523.